Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. In particular, the compound may be used as a preferential agonist of Cannabinoid Receptor 2.

Abstract: Embodiments of the invention are directed toward systems and methods that execute legacy semiconductor applications using a non-legacy controller. In some embodiments a hardware abstraction layer and/or an emulator can be used to provide communication between a non-legacy operating system and legacy components including legacy applications. In some embodiments various methods and/or devices can be used to emulate and/or translate communications between legacy and non-legacy components.

Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: A method for ventilator suction management. The method includes accessing data associated with a patient, wherein the patient is associated with a ventilator; analyzing the data; and determining that suction is needed on the patient based on the analyzed data.

Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: A monitoring system for multiple medical ventilators is provided. In one aspect, the monitoring system includes a memory that includes instructions, and a processor. The processor is configured to execute the instructions to receive data for a plurality of medical ventilators, and identify a configuration for each of the plurality of medical ventilators from the received data for the plurality of medical ventilators. The processor is also configured to execute the instructions to associate each patient with a respective one of the plurality of medical ventilators, determine an identification and status for each patient associated with one of the plurality of medical ventilators, and provide, for display, information indicative of the configuration of each of the plurality of medical ventilators and indicative of the identification and status of each patient associated with one of the plurality of medical ventilators. Methods and machine-readable media are also provided.

Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.

Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Abstract: The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; —CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH2— or —(CH2)2—; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a ste

Abstract: A labeling device for a syringe that includes a first labeling subsystem adapted to print a first label having machine readable information and a second labeling subsystem adapted to print a second label having human readable information is disclosed. The first labeling subsystem includes a label applicator adapted to automatically apply the first label to a portion of the syringe. The first labeling subsystem includes a syringe clamp assembly that securely holds the syringe while the label applicator automatically applies a first label to the syringe. The second labeling subsystem includes a removal device adapted to automatically remove a backing material from the second label.

Abstract: The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.

Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The present invention is concerned with novel pyridazinone derivatives of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.

Abstract: The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; —CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH2—or —(CH2)2—; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a ster

Abstract: A method for health care facility ventilation management is described. The method includes accessing ventilator data generated by a ventilator for a patient and providing patient information of the patient for the ventilator. The patient information is configured for contextualizing the ventilator data. The method also includes providing protocols and rules for the ventilator.

Abstract: There are provided methods and apparatus for synchronized stream packing of packets that differ contextually between A/V streams in a parallel presentation. A method includes the step of identifying sub-picture/subtitle packets and/or audio packets having arrival timestamps and/or presentation timestamps that match an arrival timestamp and/or a presentation timestamp, respectively, of video packets. The method also includes the step of packing a Video Object Unit (VOBU) and/or a Transport Stream (TS) with the identified sub-picture/subtitle and audio packets and the video packets having the matching timestamps.

Abstract: Selection of an audio-visual stream from among a plurality of streams occurs by first detecting a navigation packet within at least one stream that provides information concerning the stream, as well as those streams in lie in synchronism therewith. From the navigation packet, a determination is made which other streams lie in synchronism with the one stream, which audio and sub-picture data packets exist in each stream, and as well as which highlight information properties exist for selecting among the synchronized streams. At least one of the audio data packets, sub-picture data packets, or highlight information properties undergoes modification in accordance with information about at least one other synchronized stream to allow display of a viewer selectable button or the like to select among the synchronized streams and/or be presented with differing audio and/or sub-picture contents with each stream.